Setmelanotide (brand name Imcivree) is an FDA-approved injectable peptide agonist of the melanocortin-4 receptor (MC4R) used for chronic weight management in adults and children aged 6 and older. It is specifically indicated for individuals with genetic or syndromic obesity—including POMC deficiency, PCSK1 deficiency, LEPR deficiency, and Bardet-Biedl syndrome—who experience severe hyperphagia (excessive hunger).
Unlike general-population obesity medications, setmelanotide represents precision medicine, working only for patients with documented genetic defects in the MC4R pathway. This guide covers practical dosing information, but setmelanotide is a prescription-only medication requiring specialist supervision and genetic or syndromic diagnosis.
Cost: $18,000–$25,000 per month.
Approved Dose
The standard maintenance dose of setmelanotide is 2–3 mg administered once daily via subcutaneous injection.
- Typical starting dose: 0.5–1 mg daily
- Target maintenance dose: 2–3 mg daily
- Administration route: Subcutaneous injection only (not oral)
- Frequency: Once daily, every day
Titration Schedule
Setmelanotide is typically introduced at a lower dose and gradually increased over several weeks to minimize side effects, particularly nausea during the early adjustment phase.
Example titration protocol:
- Week 1–2: 0.5 mg daily
- Week 3–4: 1 mg daily
- Week 5–6: 1.5 mg daily
- Week 7 onward: 2–3 mg daily (maintenance)
Individual titration speed depends on tolerability, specialist guidance, and patient response. Some patients may reach 2–3 mg within 4–6 weeks; others may require 8–12 weeks for full dose escalation.
Setmelanotide dosing does not vary significantly by condition type; however, clinical response and optimal maintenance doses may differ slightly:
POMC or PCSK1 Deficiency
- Standard dose: 2–3 mg daily
- Expected response: Substantial weight loss (20–51 kg over 12–42 weeks in clinical studies); marked reduction in hunger
- Dosing note: Some patients may stabilize on 2 mg; others benefit from 3 mg. Dose adjustments should be made under specialist guidance based on hunger scores and weight trajectory.
LEPR (Leptin Receptor) Deficiency
- Standard dose: 2–3 mg daily
- Expected response: 10–48% of patients achieve ≥10% weight loss at 52 weeks; sustained hunger reduction
- Dosing note: Similar to POMC/PCSK1 deficiency. Titration and maintenance follow the standard protocol.
Bardet-Biedl Syndrome (BBS)
- Standard dose: 2–3 mg daily
- Expected response: 47–63% of patients achieve ≥10% weight loss at 52 weeks
- Dosing note: Pediatric patients (aged 6–11) and adolescents (aged 12–17) use the same maintenance range; pediatric trials employed doses of 0.01–0.03 mg/kg, typically resulting in 2–3 mg daily for children ≥6 years.
Injection Technique
Setmelanotide is administered via subcutaneous injection, meaning the medication is injected into the layer of fat beneath the skin (not into muscle or vein).
Injection sites include:
- Abdomen (preferred)
- Upper arms
- Thighs
- Buttocks
Rotate injection sites daily to reduce local irritation and injection site reactions (the most common adverse event).
Administration Steps
- Prepare the dose: Withdraw the prescribed amount (e.g., 2–3 mg) from the vial using a sterile syringe and needle.
- Clean the injection site: Use an alcohol swab to sanitize the skin.
- Insert the needle: At a 45–90-degree angle, insert the needle into the subcutaneous layer.
- Inject slowly: Depress the plunger to deliver the dose over 5–10 seconds.
- Remove and dispose: Withdraw the needle and dispose of the syringe in a sharps container.
- Document: Record the injection site and time for rotation purposes.
Important: Patients should receive training from a healthcare provider or nurse on proper injection technique before self-administering at home.
Continuous vs. Cycled Administration
Setmelanotide is designed as a continuous, daily therapy for chronic weight management. Clinical trials employed uninterrupted daily dosing for 12–52 weeks and beyond.
Key points:
- No evidence supports cycled dosing (e.g., on/off weeks).
- Treatment is intended as ongoing, not as a short-term intervention.
- Patients in clinical trials who paused treatment (e.g., due to adverse events) experienced symptom recurrence, indicating the need for continuous dosing to maintain therapeutic benefit.
Long-Term Treatment
The longest reported continuous treatment duration in clinical trials is approximately 46 months, with sustained weight loss and hunger reduction. Specialist supervision is required throughout treatment, with regular monitoring for:
- Efficacy (weight loss, hunger scores)
- Adverse events (injection site reactions, hyperpigmentation, mood changes)
- Safety labs and clinical assessments
Beginner Protocol
If you are newly prescribed setmelanotide:
- Start low, go slow: Begin at 0.5–1 mg daily for 1–2 weeks.
- Monitor tolerability: Track nausea, injection site reactions, and mood.
- Titrate gradually: Increase by 0.5–1 mg every 1–2 weeks as tolerated.
- Reach maintenance: Aim for 2–3 mg daily over 4–8 weeks.
- Stabilize: Remain on 2–3 mg daily with ongoing specialist follow-up.
Advanced/Optimized Protocol
Once stabilized on a maintenance dose, optimization may include:
- Dose adjustment within range: If response is suboptimal at 2 mg, increase to 2.5–3 mg under specialist guidance.
- Injection site rotation: Establish a systematic 7–10 site rotation to minimize local reactions.
- Time-of-day standardization: Take injections at the same time each day to maintain consistent MC4R signaling and hunger suppression.
- Response monitoring: Track weight, hunger scores (via standardized questionnaires), and metabolic markers every 4–12 weeks.
1. Skipping Days or Stopping Abruptly
Setmelanotide requires continuous daily dosing. Missed doses reduce efficacy and may trigger hunger rebound. Do not skip doses or stop treatment without specialist guidance.
2. Rapid Dose Escalation
Jumping from 0.5 mg to 3 mg in one week increases nausea and side effects. Titrate slowly over 4–8 weeks to allow adaptation.
3. Using the Same Injection Site Repeatedly
Repeated injections at one site cause erythema, induration (hardening), and discomfort. Rotate sites systematically to maintain injection tolerability.
4. Self-Adjusting Doses Without Specialist Input
Setmelanotide carries an FDA black box warning for depression and suicidal ideation. All dose changes must be supervised by a prescribing specialist, not adjusted independently.
5. Expecting Rapid Results Before Titration is Complete
Weight loss typically accelerates once maintenance dose (2–3 mg) is reached, usually 4–8 weeks into treatment. Do not increase dose prematurely if results are slow during titration.
6. Using Setmelanotide for General Obesity
Setmelanotide is approved only for genetic or syndromic obesity (POMC/PCSK1/LEPR deficiency or Bardet-Biedl syndrome). Off-label use in common polygenic obesity is inappropriate and not supported by evidence.
7. Forgetting Mood Monitoring
Due to the black box warning for depression and suicidal ideation, mood and mental health must be monitored throughout treatment. Report any mood changes, hopelessness, or suicidal thoughts to your specialist immediately.
| Parameter | Details |
|---|
| Maintenance Dose | 2–3 mg daily |
| Route | Subcutaneous injection |
| Frequency | Once daily (every day) |
| Starting Dose | 0.5–1 mg daily |
| Titration Duration | 4–12 weeks to reach maintenance |
| Typical Titration Step | Increase by 0.5–1 mg every 1–2 weeks |
| Treatment Duration | Continuous (long-term, no cycling) |
| Injection Sites | Abdomen, arms, thighs, buttocks (rotate daily) |
| Expected Weight Loss | 10–51 kg over 12–52 weeks (varies by genetic indication) |
| Cost | $18,000–$25,000/month |
| Monitoring Frequency | Every 4–12 weeks (weight, hunger, mood, labs) |
| Special Precautions | Black box warning: depression/suicidal ideation monitoring required |
Setmelanotide is not a one-size-fits-all medication. Dosing, titration speed, and maintenance levels should always be determined and monitored by a specialist familiar with MC4R agonist therapy and the patient's specific genetic or syndromic diagnosis.
This guide is educational and does not constitute medical advice. Do not use setmelanotide without a prescription, genetic/syndromic diagnosis, and specialist supervision. Do not adjust doses independently, skip doses, or use the medication off-label.
Key takeaway for dosing: Start at 0.5–1 mg, titrate gradually to 2–3 mg over 4–8 weeks, inject subcutaneously once daily, rotate injection sites, and maintain continuous daily dosing under specialist oversight.